Additionally, the prostate-specific membrane antigen (PSMA) inhibitor 177Lu-PSMA-617 (PLUVICTOTM) has been recently approved by the FDA to treat metastatic castration-resistant prostate cancer (PCa) [1,2]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.